

**Table 14.2-2.74: Summary of Corneal Sensitivity (Full Analysis Set)**

Parameter	Visit	Statistic	Pro-ocular 0.5% (N=29) n (%)	Pro-ocular 1% (N=30) n (%)	Placebo (N=30) n (%)	Overall (N=89) n (%)
Superior Nasal Sensitivity	Baseline	n (missing)	29 (0)	30 (0)	30 (0)	89 (0)
		Mean (SD)	4.0 (2.57)	5.3 (1.46)	4.0 (2.36)	4.5 (2.24)
		Median	6.0	6.0	5.0	6.0
		Q1, Q3	0.6, 6.0	5.0, 6.0	0.6, 6.0	4.0, 6.0
		Min, Max	1, 6	1, 6	1, 6	1, 6
	Week 4	n (missing)	28 (1)	29 (1)	30 (0)	87 (2)
		Mean (SD)	4.1 (2.49)	5.4 (1.43)	4.1 (2.41)	4.5 (2.23)
		Median	5.6	6.0	5.3	6.0
		Q1, Q3	0.6, 6.0	5.5, 6.0	0.6, 6.0	4.0, 6.0
		Min, Max	1, 6	1, 6	1, 6	1, 6
	Week 4 change from Baseline	n (missing)	28 (1)	29 (1)	30 (0)	87 (2)
		Mean (SD)	0.1 (1.02)	0.1 (0.27)	0.1 (0.38)	0.1 (0.63)
		Median	0.0	0.0	0.0	0.0
		Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0
		Min, Max	-1, 5	-0, 1	-1, 1	-1, 5

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T\_corsen.sas

Production date (time): 04APR2023 (11:46)

Page 1 of 7

**Table 14.2-2.74: Summary of Corneal Sensitivity (Full Analysis Set)**

Parameter	Visit	Statistic	Pro-ocular 0.5% (N=29) n (%)	Pro-ocular 1% (N=30) n (%)	Placebo (N=30) n (%)	Overall (N=89) n (%)
Superior Nasal Sensitivity	Week 12	n (missing)	24 (5)	28 (2)	27 (3)	79 (10)
		Mean (SD)	4.1 (2.55)	5.3 (1.52)	4.2 (2.43)	4.5 (2.23)
		Median	6.0	6.0	5.5	6.0
		Q1, Q3	0.6, 6.0	5.0, 6.0	0.6, 6.0	4.0, 6.0
		Min, Max	1, 6	1, 6	1, 6	1, 6
	Week 12 change from Baseline	n (missing)	24 (5)	28 (2)	27 (3)	79 (10)
		Mean (SD)	-0.0 (0.38)	-0.0 (0.69)	0.2 (0.54)	0.1 (0.56)
		Median	0.0	0.0	0.0	0.0
		Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 0.5	0.0, 0.0
		Min, Max	-1, 1	-3, 2	-1, 2	-3, 2
Inferior Nasal Sensitivity	Baseline	n (missing)	29 (0)	30 (0)	30 (0)	89 (0)
		Mean (SD)	3.9 (2.53)	5.4 (1.46)	4.0 (2.34)	4.4 (2.24)
		Median	5.5	6.0	5.0	6.0
		Q1, Q3	0.6, 6.0	5.0, 6.0	0.6, 6.0	3.5, 6.0
		Min, Max	1, 6	1, 6	1, 6	1, 6

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T\_corsen.sas

Production date (time): 04APR2023 (11:46)

Page 2 of 7

**Table 14.2-2.74: Summary of Corneal Sensitivity (Full Analysis Set)**

Parameter	Visit	Statistic	Pro-ocular 0.5% (N=29) n (%)	Pro-ocular 1% (N=30) n (%)	Placebo (N=30) n (%)	Overall (N=89) n (%)
Inferior Nasal Sensitivity	Week 4	n (missing)	28 (1)	29 (1)	30 (0)	87 (2)
		Mean (SD)	4.1 (2.51)	5.4 (1.45)	4.0 (2.39)	4.5 (2.23)
		Median	5.9	6.0	5.0	6.0
		Q1, Q3	0.6, 6.0	5.5, 6.0	0.6, 6.0	4.0, 6.0
		Min, Max	1, 6	1, 6	1, 6	1, 6
	Week 4 change from Baseline	n (missing)	28 (1)	29 (1)	30 (0)	87 (2)
		Mean (SD)	0.3 (1.08)	0.0 (0.33)	0.1 (0.34)	0.1 (0.68)
		Median	0.0	0.0	0.0	0.0
		Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0
		Min, Max	-1, 5	-1, 1	-1, 1	-1, 5
	Week 12	n (missing)	24 (5)	28 (2)	27 (3)	79 (10)
		Mean (SD)	4.0 (2.49)	5.3 (1.53)	4.2 (2.43)	4.5 (2.23)
		Median	5.0	6.0	5.5	6.0
		Q1, Q3	0.6, 6.0	5.3, 6.0	0.6, 6.0	4.0, 6.0
		Min, Max	1, 6	1, 6	1, 6	1, 6

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T\_corsen.sas

Production date (time): 04APR2023 (11:46)

Page 3 of 7

**Table 14.2-2.74: Summary of Corneal Sensitivity (Full Analysis Set)**

Parameter	Visit	Statistic	Pro-ocular 0.5% (N=29) n (%)	Pro-ocular 1% (N=30) n (%)	Placebo (N=30) n (%)	Overall (N=89) n (%)
Inferior Nasal Sensitivity	Week 12 change from Baseline	n (missing)	24 (5)	28 (2)	27 (3)	79 (10)
		Mean (SD)	0.0 (0.31)	0.0 (0.72)	0.2 (0.56)	0.1 (0.57)
		Median	0.0	0.0	0.0	0.0
		Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 0.5	0.0, 0.0
		Min, Max	-1, 1	-3, 2	-1, 2	-3, 2
Superior Temporal Sensitivity	Baseline	n (missing)	29 (0)	30 (0)	30 (0)	89 (0)
		Mean (SD)	4.0 (2.54)	5.3 (1.49)	3.9 (2.34)	4.4 (2.24)
		Median	5.5	6.0	5.0	6.0
		Q1, Q3	0.6, 6.0	5.5, 6.0	0.6, 6.0	3.5, 6.0
		Min, Max	1, 6	1, 6	1, 6	1, 6
	Week 4	n (missing)	28 (1)	29 (1)	30 (0)	87 (2)
		Mean (SD)	4.1 (2.49)	5.4 (1.46)	4.1 (2.41)	4.5 (2.24)
		Median	5.6	6.0	5.3	6.0
		Q1, Q3	0.6, 6.0	6.0, 6.0	0.6, 6.0	4.0, 6.0
		Min, Max	1, 6	1, 6	1, 6	1, 6

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T\_corsen.sas

Production date (time): 04APR2023 (11:46)

Page 4 of 7

**Table 14.2-2.74: Summary of Corneal Sensitivity (Full Analysis Set)**

Parameter	Visit	Statistic	Pro-ocular 0.5% (N=29) n (%)	Pro-ocular 1% (N=30) n (%)	Placebo (N=30) n (%)	Overall (N=89) n (%)
Superior Temporal Sensitivity	Week 4 change from Baseline	n (missing)	28 (1)	29 (1)	30 (0)	87 (2)
		Mean (SD)	0.2 (0.98)	0.1 (0.28)	0.1 (0.42)	0.1 (0.62)
		Median	0.0	0.0	0.0	0.0
		Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0
		Min, Max	-1, 5	-0, 1	-1, 1	-1, 5
	Week 12	n (missing)	24 (5)	28 (2)	27 (3)	79 (10)
		Mean (SD)	4.1 (2.55)	5.3 (1.52)	4.2 (2.43)	4.5 (2.23)
		Median	6.0	6.0	5.5	6.0
		Q1, Q3	0.6, 6.0	5.3, 6.0	0.6, 6.0	4.0, 6.0
		Min, Max	1, 6	1, 6	1, 6	1, 6
	Week 12 change from Baseline	n (missing)	24 (5)	28 (2)	27 (3)	79 (10)
		Mean (SD)	0.0 (0.39)	0.0 (0.80)	0.3 (0.58)	0.1 (0.62)
		Median	0.0	0.0	0.0	0.0
		Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 0.5	0.0, 0.0
		Min, Max	-1, 2	-3, 2	-1, 2	-3, 2

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T\_corsen.sas

Production date (time): 04APR2023 (11:46)

Page 5 of 7

**Table 14.2-2.74: Summary of Corneal Sensitivity (Full Analysis Set)**

Parameter	Visit	Statistic	Pro-ocular 0.5% (N=29) n (%)	Pro-ocular 1% (N=30) n (%)	Placebo (N=30) n (%)	Overall (N=89) n (%)
Inferior Temporal Sensitivity	Baseline	n (missing)	29 (0)	30 (0)	30 (0)	89 (0)
		Mean (SD)	4.0 (2.55)	5.4 (1.46)	3.9 (2.34)	4.4 (2.24)
		Median	5.5	6.0	5.0	6.0
		Q1, Q3	0.6, 6.0	5.5, 6.0	0.6, 6.0	4.0, 6.0
		Min, Max	1, 6	1, 6	1, 6	1, 6
	Week 4	n (missing)	28 (1)	29 (1)	30 (0)	87 (2)
		Mean (SD)	4.1 (2.52)	5.4 (1.45)	4.0 (2.38)	4.5 (2.23)
		Median	5.9	6.0	5.0	6.0
		Q1, Q3	0.6, 6.0	6.0, 6.0	0.6, 6.0	4.0, 6.0
		Min, Max	1, 6	1, 6	1, 6	1, 6
	Week 4 change from Baseline	n (missing)	28 (1)	29 (1)	30 (0)	87 (2)
		Mean (SD)	0.2 (1.06)	0.0 (0.33)	0.1 (0.37)	0.1 (0.67)
		Median	0.0	0.0	0.0	0.0
		Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0
		Min, Max	-1, 5	-1, 1	-1, 1	-1, 5

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T\_corsen.sas

Production date (time): 04APR2023 (11:46)

Page 6 of 7

**Table 14.2-2.74: Summary of Corneal Sensitivity (Full Analysis Set)**

Parameter	Visit	Statistic	Pro-ocular 0.5% (N=29) n (%)	Pro-ocular 1% (N=30) n (%)	Placebo (N=30) n (%)	Overall (N=89) n (%)
Inferior Temporal Sensitivity	Week 12	n (missing)	24 (5)	28 (2)	27 (3)	79 (10)
		Mean (SD)	4.0 (2.53)	5.3 (1.52)	4.2 (2.43)	4.5 (2.23)
		Median	5.5	6.0	5.5	6.0
		Q1, Q3	0.6, 6.0	5.3, 6.0	0.6, 6.0	4.0, 6.0
		Min, Max	1, 6	1, 6	1, 6	1, 6
	Week 12 change from Baseline	n (missing)	24 (5)	28 (2)	27 (3)	79 (10)
		Mean (SD)	0.0 (0.39)	-0.1 (0.70)	0.3 (0.58)	0.1 (0.59)
		Median	0.0	0.0	0.0	0.0
		Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 0.5	0.0, 0.0
		Min, Max	-1, 2	-3, 2	-1, 2	-3, 2

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T\_corsen.sas

Production date (time): 04APR2023 (11:46)

Page 7 of 7

**Table 14.2-2.75: Analysis of Corneal Sensitivity (Full Analysis Set)**

Parameter	Visit		Adjusted Mean		P-value
			n	LS Mean (95% CI)	
Superior Nasal Sensitivity	Week 4	1% Pro-ocular	29	0.11 (-0.16, 0.39)	-
		0.5% Pro-ocular	28	0.08 (-0.19, 0.36)	-
		Placebo	30	0.05 (-0.23, 0.33)	-
		LS Mean Difference, 1% Pro-ocular – Placebo (95% CI)		0.06 (-0.28, 0.40)	0.722
		LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI)		0.03 (-0.30, 0.37)	0.853
	Week 12	1% Pro-ocular	28	-0.04 (-0.29, 0.22)	-
		0.5% Pro-ocular	24	-0.04 (-0.31, 0.23)	-
		Placebo	27	0.17 (-0.09, 0.44)	-
		LS Mean Difference, 1% Pro-ocular – Placebo (95% CI)		-0.21 (-0.53, 0.11)	0.191
		LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI)		-0.21 (-0.53, 0.10)	0.185
Inferior Nasal Sensitivity	Week 4	1% Pro-ocular	29	0.06 (-0.23, 0.35)	-
		0.5% Pro-ocular	28	0.25 (-0.04, 0.54)	-
		Placebo	30	0.02 (-0.28, 0.31)	-
		LS Mean Difference, 1% Pro-ocular – Placebo (95% CI)		0.04 (-0.32, 0.41)	0.810
		LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI)		0.23 (-0.12, 0.59)	0.192

N: total number of patients per group. n: number of non-missing observations. CI: Confidence Interval. The change from baseline is analysed by means of an ANCOVA model by Visit with treatment as fixed effect and baseline measure and stratification factor (male, female: menopausal, female: non-menopausal) as covariates.

Program: T\_aconnei.sas

Production date (time): 12MAY2023 (11:25)

Page 1 of 3



**Table 14.2-2.75: Analysis of Corneal Sensitivity (Full Analysis Set)**

Parameter	Visit		Adjusted Mean		P-value
			n	LS Mean (95% CI)	
Inferior Nasal Sensitivity	Week 12	1% Pro-ocular	28	0.00 (-0.26, 0.26)	-
		0.5% Pro-ocular	24	0.00 (-0.27, 0.28)	-
		Placebo	27	0.20 (-0.07, 0.47)	-
		LS Mean Difference, 1% Pro-ocular – Placebo (95% CI)		-0.21 (-0.53, 0.12)	0.205
		LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI)		-0.20 (-0.52, 0.12)	0.220
Superior Temporal Sensitivity	Week 4	1% Pro-ocular	29	0.08 (-0.19, 0.35)	-
		0.5% Pro-ocular	28	0.09 (-0.18, 0.36)	-
		Placebo	30	0.03 (-0.24, 0.30)	-
		LS Mean Difference, 1% Pro-ocular – Placebo (95% CI)		0.05 (-0.29, 0.38)	0.780
		LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI)		0.06 (-0.27, 0.39)	0.729
	Week 12	1% Pro-ocular	28	-0.01 (-0.30, 0.27)	-
		0.5% Pro-ocular	24	-0.01 (-0.32, 0.29)	-
		Placebo	27	0.19 (-0.10, 0.49)	-
		LS Mean Difference, 1% Pro-ocular – Placebo (95% CI)		-0.21 (-0.56, 0.15)	0.248
		LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI)		-0.21 (-0.56, 0.15)	0.247

N: total number of patients per group. n: number of non-missing observations. CI: Confidence Interval. The change from baseline is analysed by means of an ANCOVA model by Visit with treatment as fixed effect and baseline measure and stratification factor (male, female: menopausal, female: non-menopausal) as covariates.

Program: T\_aconnei.sas

Production date (time): 12MAY2023 (11:25)

Page 2 of 3

**Table 14.2-2.75: Analysis of Corneal Sensitivity (Full Analysis Set)**

Parameter	Visit		Adjusted Mean		P-value
			n	LS Mean (95% CI)	
Inferior Temporal Sensitivity	Week 4	1% Pro-ocular	29	0.06 (-0.23, 0.35)	-
		0.5% Pro-ocular	28	0.18 (-0.11, 0.46)	-
		Placebo	30	0.03 (-0.26, 0.32)	-
		LS Mean Difference, 1% Pro-ocular – Placebo (95% CI)		0.03 (-0.33, 0.39)	0.869
		LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI)		0.14 (-0.21, 0.50)	0.416
	Week 12	1% Pro-ocular	28	-0.06 (-0.33, 0.20)	-
		0.5% Pro-ocular	24	-0.03 (-0.31, 0.25)	-
		Placebo	27	0.22 (-0.05, 0.50)	-
		LS Mean Difference, 1% Pro-ocular – Placebo (95% CI)		-0.29 (-0.61, 0.04)	0.087
		LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI)		-0.25 (-0.58, 0.08)	0.130

N: total number of patients per group. n: number of non-missing observations. CI: Confidence Interval. The change from baseline is analysed by means of an ANCOVA model by Visit with treatment as fixed effect and baseline measure and stratification factor (male, female: menopausal, female: non-menopausal) as covariates.

Program: T\_aconnei.sas

Production date (time): 12MAY2023 (11:25)

Page 3 of 3